Article
Recent developments in myelodysplastic syndromes.
Blood - 30 Oct 2014
Bejar Rafael, Steensma David P
Abstract excerpt
Once thought to be rare disorders, the myelodysplastic syndromes (MDS) are now recognized as among the most common hematological neoplasms, probably affecting >30 000 patients per year in the United States. US regulatory approval of azacitidine, decitabine, and lenalidomide between 2004 and 2006 seemed to herald a new era in the development of disease-modifying therapies for MDS, but there have been no further...
Topics
Join the communities discussing this publication.